Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3295668 Erbumine in Relapsed/Refractory Neuroblastoma
NCT04106219Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 1, open-label trial of LY3295668 in neuroblastoma (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with Dose Limiting Toxicities, Overall Response Rate and 1 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
LY3295668
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04106219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106219.